At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
NOX66 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Ia/Ib and Potential Phase IIa Study of the Safety and Pharmacokinetics of NOX66 Both as a Monotherapy and in Combination With Carboplatin in Patients With Refractory Solid Tumours
In Brief
A Phase 2 clinical trial evaluating NOX66 and Carboplatin for Cancer. Completed, enrolled 19 participants across 4 sites.
Detailed Summary
The study evaluates the safety and activity of NOX66 in patients with refractory solid tumors that are non responsive to standard therapies. This is a two part with a potential third part, open-label, multicenter, dose escalation study of NOX66 as monotherapy and in combination with carboplatin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesGeorgia
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartMar 2017
Primary CompletionDec 2018
Study CompletionJan 2019
TodayJul 2026
First PostedOct 21, 2016
Enrollment StartMar 3, 2017
Primary CompletionDec 31, 2018
Study CompletionJan 10, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.7 years ago
Interventions
NOX66drug
NOX66 administration
Carboplatindrug
Carboplatin administration